Ads
related to: catastrophic thrombosis treatment medications names available- Watch Webinars
Learn about hot topics
in healthcare.
- Contact Us
Request a quote
or get help with customer support.
- RxAdvanced
Premier training programs for
highly-skilled, expert pharmacists.
- Natural Medicines
The world's most authoritative
database on natural medicines.
- Search For TRC Solutions
Find the right solution that meets
your education & training needs.
- Find Continuing Education
Receive accredited CE that meets
state & national requirements.
- Watch Webinars
wexnermedical.osu.edu has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
Antiplatelet drugs alter the platelet activation at the site of vascular damage crucial to the development of arterial thrombosis. Aspirin and Triflusal irreversibly inhibits the enzyme COX, resulting in reduced platelet production of TXA 2 (thromboxane – powerful vasoconstrictor that lowers cyclic AMP and initiates the platelet release ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Catastrophic antiphospholipid syndrome (CAPS), also known as Asherson's syndrome, is a rare autoimmune disease in which widespread, intravascular clotting causes multi-organ failure. [1] The syndrome is caused by antiphospholipid antibodies that target a group of proteins in the body that are associated with phospholipids .
An antithrombotic agent is a drug that reduces the formation of blood clots (). [1] [2] Antithrombotics can be used therapeutically for prevention (primary prevention, secondary prevention) or treatment of a dangerous blood clot (acute thrombus).
For many years dual treatment with the cyclooxygenase-1 (COX-1) inhibitor aspirin and clopidogrel was routine practice and served as the main antiplatelet agents for the prevention of thrombotic events as they have the capability to powerfully manipulate platelet biology, which plays a central part in thrombosis.
Ximelagatran showed good efficacy compared with warfarin in several trials in prevention and treatment of deep vein thrombosis and as thromboprophylaxis in atrial fibrillation. [1] Development was stopped by manufacturer AstraZeneca , however, because of reports of liver enzyme derangements and liver failure .
Ads
related to: catastrophic thrombosis treatment medications names availablewexnermedical.osu.edu has been visited by 10K+ users in the past month